MXPA06007964A - Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia. - Google Patents

Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia.

Info

Publication number
MXPA06007964A
MXPA06007964A MXPA06007964A MXPA06007964A MXPA06007964A MX PA06007964 A MXPA06007964 A MX PA06007964A MX PA06007964 A MXPA06007964 A MX PA06007964A MX PA06007964 A MXPA06007964 A MX PA06007964A MX PA06007964 A MXPA06007964 A MX PA06007964A
Authority
MX
Mexico
Prior art keywords
compound
formula
salt
anesthesia
pharmaceutically acceptable
Prior art date
Application number
MXPA06007964A
Other languages
English (en)
Spanish (es)
Inventor
Mary Anne Hickman
Christine Edna Miskell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA06007964A publication Critical patent/MXPA06007964A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MXPA06007964A 2004-01-30 2005-01-06 Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia. MXPA06007964A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54069704P 2004-01-30 2004-01-30
PCT/IB2005/000010 WO2005082366A1 (en) 2004-01-30 2005-01-06 Nk-1 receptor antagonists anesthesia recovery

Publications (1)

Publication Number Publication Date
MXPA06007964A true MXPA06007964A (es) 2007-01-26

Family

ID=34910695

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06007964A MXPA06007964A (es) 2004-01-30 2005-01-06 Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia.

Country Status (14)

Country Link
US (1) US20070155782A1 (cg-RX-API-DMAC7.html)
EP (1) EP1713479A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007519701A (cg-RX-API-DMAC7.html)
KR (1) KR100880391B1 (cg-RX-API-DMAC7.html)
CN (1) CN1913893A (cg-RX-API-DMAC7.html)
AU (1) AU2005216706B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507325A (cg-RX-API-DMAC7.html)
CA (1) CA2554823A1 (cg-RX-API-DMAC7.html)
IL (1) IL176830A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06007964A (cg-RX-API-DMAC7.html)
NO (1) NO20062965L (cg-RX-API-DMAC7.html)
RU (1) RU2337685C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005082366A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605149B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034099T2 (en) 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
RU2489765C1 (ru) * 2012-01-10 2013-08-10 Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") Способ изготовления газонаполненного разрядника
CN114984223B (zh) * 2022-05-31 2023-06-20 中国人民解放军陆军军医大学第二附属医院 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung
WO2026099213A1 (fr) * 2024-11-05 2026-05-15 Ceva Sante Animale Compositions comprenant du maropitant base et leurs utilisations
FR3168163A1 (fr) * 2024-11-05 2026-05-08 Ceva Sante Animale Compositions aqueuses comprenant du maropitant et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US540897A (en) 1895-06-11 Harold f
US540644A (en) 1895-06-11 del yalle
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Also Published As

Publication number Publication date
WO2005082366A1 (en) 2005-09-09
BRPI0507325A (pt) 2007-07-03
AU2005216706A1 (en) 2005-09-09
EP1713479A1 (en) 2006-10-25
WO2005082366A8 (en) 2005-12-15
IL176830A0 (en) 2006-10-31
KR100880391B1 (ko) 2009-01-30
US20070155782A1 (en) 2007-07-05
NO20062965L (no) 2006-07-21
ZA200605149B (en) 2007-11-28
RU2006126828A (ru) 2008-03-10
JP2007519701A (ja) 2007-07-19
RU2337685C2 (ru) 2008-11-10
AU2005216706B2 (en) 2007-11-29
CA2554823A1 (en) 2005-09-09
KR20060127934A (ko) 2006-12-13
CN1913893A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
JP6929479B2 (ja) 激越の治療のための舌下デクスメデトミジンの使用
KR100298808B1 (ko) 외상손상과관련된신경학적병변의치료를위한,릴루졸을포함하는제약학적조성물
EP2916846B1 (en) Neuroactive steroids and their use to facilitate neuroprotection
US20250099430A1 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
CA2176298C (en) A single high dose fluoroquinolone treatment
SI21025A (sl) Analgetski sestavki, ki vsebujejo buprenorfin
CZ284363B6 (cs) Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů
AU2005216706B2 (en) NK-1 receptor antagonists anesthesia recovery
Dahl et al. Immediate and prolonged effects of pre–versus postoperative epidural analgesia with bupivacaine and morphine on pain at rest and during mobilisation after total knee arthroplasty
Bufalari et al. Preemptive carprofen for peri-operative analgesia in dogs undergoing Tibial Plateau Leveling Osteotomy (TPLO): a prospective, randomized, blinded, placebo controlled clinical trial
US10925864B2 (en) Stable liquid injectable solution of midazolam and pentazocine
DE60215525T2 (de) Kombination aus quetiapin und zolmitriptan
DE102020112143B4 (de) Nicotin - Corona
KR101442874B1 (ko) 만성 폐색성 폐질환 치료제
HK1100640A (en) Nk-1 receptor antagonists anesthesia recovery
CA2986941C (en) New use of isoquinoline derivatives for diabetic wound healing
DE102014115951A1 (de) Zusammensetzungen, die Finafloxacin und Tris enthalten
HK1022649B (en) The use of levobupivacaine in paediatric surgery

Legal Events

Date Code Title Description
FA Abandonment or withdrawal